4-HO-DSBT

4-HO-DSBT structure

4-HO-DSBT: A Deep Dive into Its Serotonergic Mechanism[edit | edit source]

4-HO-DSBT or 4-hydroxy-N,N-di-sec-butyltryptamine, is a compound that belongs to the expansive tryptamine class. These compounds are renowned for their interactions with serotonin receptors, often resulting in varying degrees of psychoactive effects.

Historical Overview[edit | edit source]

The origins of 4-HO-DSBT can be traced back to the pioneering work of Dr. Alexander Shulgin. While Shulgin was the first to synthesize the compound, it is noteworthy that he did not carry out any tests on it^[1]. His documentation in the renowned book "TiHKAL" (Tryptamines I Have Known And Loved) provides an archival insight into its synthesis.

Pharmacological Profile[edit | edit source]

Serotonin Receptor Agonism: 4-HO-DSBT acts primarily as an agonist at the serotonin receptors. Agonism at these receptors is indicative of the compound's potential to produce psychoactive effects, given the central role of serotonin in mood regulation and perception.

Comparison with Isomers: Subsequent in vitro studies have differentiated 4-HO-DSBT from its n-butyl and isobutyl isomers. The s-butyl derivative (i.e., 4-HO-DSBT) was found to have a higher potency than its counterparts^[2].

5-HT2A Receptor Affinity: The 5-HT2A receptor affinity of 4-HO-DSBT is akin to that of MiPT, positioning it as a potent compound in the serotonergic agonism spectrum^[3].

Selectivity over 5-HT1A and 5-HT2B: One of the distinguishing features of 4-HO-DSBT is its heightened selectivity for the 5-HT2A receptor over the 5-HT1A and 5-HT2B subtypes. Such selectivity offers potential advantages in minimizing off-target effects and highlights its unique pharmacodynamic profile^[4].

Implications for Research and Medicine[edit | edit source]

Given its distinctive serotonergic profile, 4-HO-DSBT holds promise as a molecular tool for studying the serotonin system. Understanding its mechanism can provide insights into mood disorders, cognition, and perception. Further research into its safety profile, pharmacokinetics, and potential therapeutic applications is essential.

Conclusion[edit | edit source]

4-HO-DSBT, an intricate compound synthesized by Dr. Alexander Shulgin, offers a fascinating glimpse into the world of tryptamines and their interactions with the serotonin system. As researchers delve deeper into its pharmacological properties, the compound might pave the way for novel therapeutic avenues and a deeper understanding of serotonergic signaling.

References[edit | edit source]

↑ Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.
↑ Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.
↑ Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.
↑ Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[tihkal-1] Shulgin, A., & Shulgin, A. (1997). TiHKAL: The Continuation. Transform Press.

[research1-2] Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131-181.

[research2-3] Ray, T. S. (2010). Psychedelics and the human receptorome. PLoS One, 5(2), e9019.

[selectivity3-4] Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381.

[1]

[2]

[3]

[4]